Obesity care's second act

Obesity care is splitting into two phases, and the second one is starting to matter more than the first. The first phase was losing weight on GLP-1s like Ozempic, Wegovy, and Mounjaro. The second phase, keeping it off after the patient stops the shot, is the under-built half of the system. Rebound is the default: when the drug leaves, the body returns to baseline.

A new randomized dataset from Fractyl Health's REMAIN-1 trial points to a candidate answer. The company's Revita procedure is a one-time endoscopic treatment that resurfaces the lining of the upper small intestine. In the Midpoint Cohort of 45 patients who had tapered off tirzepatide, a single Revita session cut weight regain by about 40% versus a sham procedure at twelve months. Among patients whose ablation covered more than 14 centimeters of the duodenum, retention of GLP-1-induced weight loss rose to roughly 81%, against 48% in the sham arm.

The pattern matters more than the device. Stopping the shot is becoming a maintenance problem, and procedural candidates like Fractyl's Revita are positioning themselves for the off-ramp. The Pivotal Cohort readout, not this Midpoint Cohort, is the dataset regulators will weigh, and the trial is small and company-funded. The shape of the answer, though, has already changed: weight-loss care now has a second act, and the market for it is just opening.